A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

PHASE3

Phase

RECRUITING

Status

544

Enrollment

INDUSTRY

Sponsor class

Conditions

DRUG: TQB2102 for injection
DRUG: Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.